LRP,MRP,MDR1基因在非小细胞肺癌中的表达及其临床意义

目的 探讨肺耐药蛋白（ｌｕｎｇ ｒｅｓｉｓｔａｎｃｅ ｐｒｏｔｅｉｎ，ＬＲＰ），多药耐药蛋白（ｍｕｌｔｉｄｒｕｇ ｒｅｓｉｓｔａｎｃｅａｓｓｏｃｉａｔｅｄ ｐｒｏｔｅｉｎ，ＭＲＰ），和多药耐药基因（ｍｕｌｔｉｄｒｕｇ ｒｅｓｉｓｔａｎｅ，ＭＤＲ１）ｍＲＮＡ在非小细胞肺癌（ｎｏｎ－ｓｍａｌｌ ｃｅｌｌ ｃａｎｃｅｒ，ＮＳＣＬＣ）中的共表达及临床意义。方法 ＲＴ－ＰＣＲ检测ＮＳＣＬＣ冰冻组织中上述耐药

Expression of LRP, MRP and MDR1 in non-small-cell lung cancer and its clinical significance]

OBJECTIVE: To detect expression of lung resistance protein (LRP), multidrug resistance-associated protein(MRP) and multidrug resistance 1(MDR1) mRNA, and its clinical significance in non-small-cell lung cancer (NSCLC). METHODS: RT-PCR was used to investigate mRNA expression of the above mentioned genes. RESULTS: The frequency of expression of LRP, MRP and MDR1 was 74.2%, 80.3% and 37.9%, respectively. A significant positive correlation was observed between LRP and MRP(r = 0.47, P = 0.001), but this association was found neither between LRP and MDR1, nor between MRP and MDR1. The expression of LRP, MRP and MDR1 did not vary with the grade of cell differentiation and TNM staging. In adenocarcinomas which responded to chemotherapy, there was lowered expression of both LRP and MRP than those which did not respond. In chemo-responsive squamous-cell carcinomas, however, this was true of LRP expression only. The median survival time of NSCLC patients with co-expressed 2 and 3 drug resistance related genes was significantly reduced. CONCLUSION: The intrinsic multidrug resistance of NSCLC involves the combined effects of LRP, MRP and MDR1.